title: Survival in allosensitized children after listing for cardiac transplantation.
abstract: BACKGROUND
  Little is known about the effect of pre-transplant alloantibody in the pediatric cardiac transplant population.
  
  
  METHODS
  All cardiac listings (n = 298) at Children's Hospital of Pittsburgh from January 1990 through February 2006 were reviewed to determine the impact of allosensitization on transplantation outcomes. Analysis focused on: (1) wait list outcomes; (2) survival from the time of listing, regardless of subsequent transplantation; (3) post-transplant graft and patient survival; and (4) post-transplant freedom from graft vasculopathy. Institutional policy required a negative, prospective crossmatch for candidates with panel-reactive antibody >20%.
  
  
  RESULTS
  Alloantibody data were available for 252 (85%) listings. Median time to transplantation was greater for sensitized vs non-sensitized subjects (2.7 months vs 1.3 months; p = 0.02). At 1 year after listing, sensitized subjects had a higher incidence of death (22% vs 8.4%; p = 0.055). Survival at all time-points after listing (regardless of transplantation) was worse for sensitized subjects (p = 0.04). Although no statistically significant differences in post-transplant graft or patient survival were noted, pre-transplant allosensitization was associated with decreased freedom from graft vasculopathy (hazard ratio [HR] 2.76, 95% confidence interval [CI] 1.18 to 6.45; p = 0.019).
  
  
  CONCLUSIONS
  A policy requiring a negative, prospective crossmatch for highly sensitized candidates is associated with longer wait list time and higher mortality after listing. The development of graft vasculopathy appears to be influenced by the presence of pre-transplant alloantibody.
authors.affiliation: Division of Pediatric Cardiology and Cardiopulmonary Transplantation, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. brian.feingold@chp.edu
authors.forename: Brian
authors.initials: B
authors.lastname: Feingold
authors.forename: Pam
authors.initials: P
authors.lastname: Bowman
authors.forename: Adriana
authors.initials: A
authors.lastname: Zeevi
authors.forename: Alin L
authors.initials: AL
authors.lastname: Girnita
authors.forename: Eric S
authors.initials: ES
authors.lastname: Quivers
authors.forename: Susan A
authors.initials: SA
authors.lastname: Miller
authors.forename: Steven A
authors.initials: SA
authors.lastname: Webber
mesh_terms: D000017:ABO Blood-Group System; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D016027:Heart Transplantation / Q000401:mortality / Q000473:pathology* / Q000502:physiology*; D006801:Humans; D007114:Immunization; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D016019:Survival Analysis; D014850:Waiting Lists
chemical_list: D000017:ABO Blood-Group System